Login to Your Account

Financings Roundup

Ardea Padding Cash Ahead of Gout Phase III, Partnering Talks

By Jennifer Boggs

Wednesday, April 7, 2010
Ardea Biosciences Inc. is shoring up its cash position on the heels of promising Phase IIb results for gout compound RDEA594, even as the buzz around the drug increases ahead of much-anticipated data from a combination study expected later this quarter. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription